Targeting C-reactive protein for the treatment of cardiovascular disease.
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Complement-mediated inflammation exacerbates the tissue injury of ischaemic necrosis in heart attacks and strokes, the most common causes of death in developed countries. Large infarct size increases immediate morbidity and mortality and, in survivors of the acute event, larger non-functional scars adversely affect long-term prognosis. There is thus an important unmet medical need for new cardioprotective and neuroprotective treatments. We have previously shown that human C-reactive protein (CRP), the classical acute-phase protein that binds to ligands exposed in damaged tissue and then activates complement, increases myocardial and cerebral infarct size in rats subjected to coronary or cerebral artery ligation, respectively. Rat CRP does not activate rat complement, whereas human CRP activates both rat and human complement. Administration of human CRP to rats is thus an excellent model for the actions of endogenous human CRP. Here we report the design, synthesis and efficacy of 1,6-bis(phosphocholine)-hexane as a specific small-molecule inhibitor of CRP. Five molecules of this palindromic compound are bound by two pentameric CRP molecules, crosslinking and occluding the ligand-binding B-face of CRP and blocking its functions. Administration of 1,6-bis(phosphocholine)-hexane to rats undergoing acute myocardial infarction abrogated the increase in infarct size and cardiac dysfunction produced by injection of human CRP. Therapeutic inhibition of CRP is thus a promising new approach to cardioprotection in acute myocardial infarction, and may also provide neuroprotection in stroke. Potential wider applications include other inflammatory, infective and tissue-damaging conditions characterized by increased CRP production, in which binding of CRP to exposed ligands in damaged cells may lead to complement-mediated exacerbation of tissue injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Heuristics may lead to bias or predictable and systematic cognitive errors, as described in Table 2.16,35”
From Artificial Intelligence and Surgical Decision-making. (2020) · cites this paper as [54]
Citations
Cites
PROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
MOLREP: an Automated Program for Molecular Replacement
Vagin, A., & Teplyakov, A. (1997) · Journal of Applied Crystallography · doi:10.1107/s0021889897006766 · Cited by 4,714
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 3,503
Self-citationWHAT IF: A molecular modeling and drug design program
Vriend, G. (1990) · Journal of Molecular Graphics · doi:10.1016/0263-7855(90)80070-v · Cited by 3,469
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Self-citationThe integration of macromolecular diffraction data
Leslie, A. G. W. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444905039107 · Cited by 1,341
The physiological structure of human C-reactive protein and its complex with phosphocholine
Thompson, D., Pepys, M. B., & Wood, S. P. (1999) · Structure · doi:10.1016/s0969-2126(99)80023-9 · Cited by 818
Self-citation
Cited by
Items 101–200 of 670
Tennent, G. A., Hutchinson, W. L., Kahan, M., Hirschfield, G. M., Gallimore, J. R., Lewin, J. F., Sabin, C. A., Dhillon, A. P., & Pepys, M. B. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.05.010 · Cited by 102
“This is potentially extremely important, because the only robustly reproducible in vivo pro-inflammatory effect shown to be specifically caused by human CRP is mediated via complement activation [33, 36 ].”
BackgroundSelf-citationKlyne, D. M., Barbe, M. F., & Hodges, P. W. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.10.003 · Cited by 107
Recognition Functions of Pentameric C-Reactive Protein in Cardiovascular Disease
Agrawal, A., Gang, T. B., & Rusiñol, A. E. (2014) · Mediators of Inflammation · doi:10.1155/2014/319215 · Cited by 95
“In another approach, pharmacological inhibition of CRP using a PCh-based compound reduced the deposition of CRP at myocardial infarcts and inhibited complement activation, indicating that the PCh-binding site of CRP participates in worsening the infarct size and that the inhibition of the PCh-binding site is a useful…”
Arenillas, J. F., Álvarez‐Sabín, J., Molina, C. A., Chacón, P. M., Fernández‐Cadenas, I., Ribó, M., Delgado, P., Rubiera, M., Peñalba, A., Rovira, À., et al. (2008) · Stroke · doi:10.1161/strokeaha.107.498600 · Cited by 98
Local Inflammation Induces Complement Crosstalk Which Amplifies the Antimicrobial Response
Zhang, J., Koh, J., Lu, J., Thiel, S., Leong, B. S. H., Sethi, S. K., He, C. Y., Ho, B., & Ding, J. L. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000282 · Cited by 109
“As an acute phase inflammation marker [23], CRP is also a multifunctional protein [3] upregulated in many diseases such as acute pneumonia [24], myocardial infarction [25] and atherothrombosis [26].”
BackgroundMacchia, E., Manoli, K., Holzer, B., Franco, C. D., Picca, R. A., Cioffi, N., Scamarcio, G., Palazzo, G., & Torsi, L. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-019-01778-2 · Cited by 111
C-reactive protein, immunothrombosis and venous thromboembolism
Dix, C. H. K., Zeller, J., Stevens, H., Eisenhardt, S. U., Shing, K. S. C. T., Nero, T. L., Morton, C. J., Parker, M. W., Peter, K., & McFadyen, J. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1002652 · Cited by 110
“Indeed, preclinical studies have consistently demonstrated a convincing role for CRP, potentially via its activating isoforms, in directly amplifying tissue damage in rodent models of myocardial infarction (39).”
BackgroundC-reactive protein and atherogenesis: From fatty streak to clinical event
Bisoendial, R. J., Kastelein, J. J. P., & Stroes, E. S. G. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.04.053 · Cited by 100
Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes
Széplaki, G., Szegedi, R., Hirschberg, K., Gombos, T., Varga, L. Á., Karádi, I., Entz, L., Széplaki, Z., Garred, P., Prohászka, Z., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.07.044 · Cited by 95
Molecular Basis of Health and Disease
Das, U. N. (2011) · Springer eBooks · doi:10.1007/978-94-007-0495-4 · Cited by 104
Strang, F., Scheichl, A., Chen, Y., Wang, X., Htun, N., Bassler, N., Eisenhardt, S. U., Habersberger, J., & Peter, K. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2011.00539.x · Cited by 94
“This agent was used in a rat model of myocardial infarction and was able to completely inhibit CRP mediated necrosis (26).”
MethodKruse, K., Janko, C., Urbonaviciute, V., Mierke, C. T., Winkler, T., Voll, R. E., Schett, G. A., Munoz, L. E., & i, M. H. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0478-8 · Cited by 106
Folate deficiency enhances the inflammatory response of macrophages
Kolb, A. F., & Petrie, L. (2012) · Molecular Immunology · doi:10.1016/j.molimm.2012.11.012 · Cited by 94
C-reactive protein enhances IgG-mediated phagocyte responses and thrombocytopenia
Kapur, R., Heitink‐Pollé, K. M. J., Porcelijn, L., Bentlage, A. E. H., Bruin, M. C. A., Visser, R., Roos, D., Schasfoort, R. B. M., de Haas, M., van der Schoot, C. E., et al. (2014) · Blood · doi:10.1182/blood-2014-05-579110 · Cited by 104
“Importantly, FNAIT and/or ITP patients may benefit from interventions aimed at reducing CRP levels or inhibiting its function.(67)”
Oxidized LDL Receptor LOX-1 Binds to C-Reactive Protein and Mediates Its Vascular Effects
Fujita, Y., Kakino, A., Nishimichi, N., Yamaguchi, S., Sato, Y., Machida, S., Cominacini, L., Delneste, Y., Matsuda, H., & Sawamura, T. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.119750 · Cited by 91
C ‐reactive protein promotes atherosclerosis by increasing LDL transcytosis across endothelial cells
Bian, F., Yang, X., Zhou, F., Wu, P., Xing, S., Xu, G., Li, W., Chi, J., Ouyang, C., Zhang, Y., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12616 · Cited by 101
“Administration of 1, 6-bis (phosphocholine)-hexane, a specific low MW inhibitor of CRP to rats undergoing acute myocardial infarction, blocked the increase in infarct size and cardiac dysfunction produced by injection of human CRP (Pepys et al., 2006).”
BackgroundThe Effects of Vitamin D Deficiency on Atrial Fibrillation
Demir, M., Uyan, U., & Melek, M. (2014) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612453762 · Cited by 95
The Dual Complexity of PTX3 in Health and Disease: A Balancing Act?
Magrini, E. I., Mantovani, A., & Garlanda, C. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.04.007 · Cited by 100
“This in turn appears to sustain their high levels of expression and consequently has often raised the question of their precise role in a given disease: are they simple markers, innocent bystanders, or players in disease pathogenesis [7–9]? In particular, CRP is a widely used biomarker of inflammation in humans; howev…”
BackgroundComplement factor H binds to denatured rather than to native pentameric C-reactive protein
Hakobyan, S., Harris, C. L., van den Berg, C. W., Fernandez-Alonso, M. C., de Jorge, E. G., de Cordoba, S. R., Rivas, G., Mangione, P., Pepys, M. B., & Morgan, B. P. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803648200 · Cited by 90
Self-citationNew insights on the regulation of cancer cachexia by N-3 polyunsaturated fatty acids
Gorjão, R., Momesso, C. M., Serdan, T. D. A., Diniz, V. L. S., Alba‐Loureiro, T. C., Cury‐Boaventura, M. F., Hatanaka, E., Levada‐Pires, A. C., Sato, F. T., Pithon‐Curi, T. C., et al. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.12.001 · Cited by 96
Function and regulation of the complement system in cardiovascular diseases
Oksjoki, R. K., Kovanen, P. T., Meri, S., & Pentikäinen, M. O. (2007) · Frontiers in bioscience · doi:10.2741/2419 · Cited by 101
“Of interest, a recent study showed that administration of Bis(PC)-H, a small molecule that blocks the ligand-binding face of CRP, significantly decreased infarct size after coronary occlusion and human CRP administration in rats (82).”
BackgroundNabata, A., Kuroki, M., Ueba, H., Hashimoto, S., Umemoto, T., Wada, H., Yasu, T., Saito, M., Momomura, S., & Kawakami, M. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.03.003 · Cited by 88
Large-Area Interfaces for Single-Molecule Label-free Bioelectronic Detection
Macchia, E., Torricelli, F., Bollella, P., Sarcina, L., Tricase, A., Franco, C. D., Österbacka, R., Kovacs-Vajna, Z. M., Scamarcio, G., & Torsi, L. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00290 · Cited by 98
Hoofnagle, A. N., Wu, M., Gosmanova, A. K., Becker, J. O., Wijsman, E. M., Brunzell, J. D., Kahn, S. E., Knopp, R. H., Lyons, T. J., & Heinecke, J. W. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.212894 · Cited by 87
C-reactive protein and cardiovascular disease: Weighing the evidence
Lowe, G. D. O., & Pepys, M. B. (2006) · Current Atherosclerosis Reports · doi:10.1007/s11883-006-0040-x · Cited by 93
Self-citationFeasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report
Ichim, T. E., Solano, F., Lara, F., Paris, E., Ugalde, F., Rodriguez, J., Minev, B., Bogin, V., Ramos, F., Woods, E. J., et al. (2010) · International Archives of Medicine · doi:10.1186/1755-7682-3-30 · Cited by 91
Elevated C-Reactive Protein in Atherosclerosis — Chicken or Egg?
Schunkert, H., & Samani, N. J. (2008) · New England Journal of Medicine · doi:10.1056/nejme0807235 · Cited by 87
Role of C-reactive protein in schizophrenia: An overview
Singh, B., & Chaudhuri, T. K. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.02.004 · Cited by 95
“Moreover, till to date the scientific world is still uncertain on the consequence of CRP deficiency as no aliment is reported which involves CRP deficiency (Pepys et al., 2006).”
Olson, M. E., Hornick, M. G., Stefanski, A., Albanna, H. R., Gjoni, A., Hall, G. D., Hart, P. C., Rajab, I. M., & Potempa, L. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264383 · Cited by 93
“From a pharmacologic perspective, the first small molecule pCRP dissociation inhibitor, which is based on a bisphosphocholine scaffold, exhibited reduced myocardial infarction volume, cardiac dysfunction, inflammation, and mCRP deposition in rats (30, 113).”
BackgroundWannamethee, S. G., Whincup, P. H., Shaper, A. G., Rumley, A., LENNON, L. T., & Lowe, G. D. O. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03574.x · Cited by 91
Role of C-reactive protein in cerebrovascular disease: a critical review
Napoli, M. D., Elkind, M. S. V., Godoy, D. A., Singh, P., Papa, F., & Popa‐Wagner, A. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.159 · Cited by 94
Zhou, J., Gan, N., Li, T., Zhou, H., Li, X., Cao, Y., Wang, L., Sang, W., & Hu, F. (2013) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2013.01.013 · Cited by 83
Immunopathogenesis of ischemia/reperfusion-associated tissue damage
Ioannou, A., Lucca, J. J. D., & Tsokos, G. C. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.07.001 · Cited by 90
Udani, J. K., Singh, B. B., Barrett, M. L., & Singh, V. J. (2009) · Nutrition Journal · doi:10.1186/1475-2891-8-48 · Cited by 94
“Therefore the ability to reduce inflammation (as measured by CRP) in overweight and obese individuals may be valuable in preventing the progression to diabetes [2,3] and heart disease [4-10].”
BackgroundJiang, H., Wang, W., Wang, C., Xie, X., & Hou, Y. (2016) · EP Europace · doi:10.1093/europace/euw088 · Cited by 102
“protein in atrial myocardium, and it is demonstrated that C-reactive protein can bind to the cardiomyocytes membrane, activate complement system, and lead to cell damage.(58) (ii) C-reactive protein”
BackgroundRole of C-Reactive Protein in Kidney Diseases
Li, J., Chen, J., Lan, H.-Y., & Tang, Y. (2022) · Kidney Diseases · doi:10.1159/000528693 · Cited by 80
Oxidative stress and wasting in cancer
Laviano, A., Meguid, M. M., Preziosa, I., & Fanelli, F. R. (2007) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e328122db94 · Cited by 80
McFadyen, J. D., Zeller, J., Potempa, L. A., Pietersz, G. A., Eisenhardt, S. U., & Peter, K. (2020) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-030-41769-7_20 · Cited by 84
Coronary Spasm is Associated With Chronic Low-Grade Inflammation
Itoh, T., Mizuno, Y., Harada, E., Yoshimura, M., Ogawa, H., & Yasue, H. (2007) · Circulation Journal · doi:10.1253/circj.71.1074 · Cited by 79
Label-Free Electrochemical Immunoassay for C-Reactive Protein
Thangamuthu, M., Santschi, C., & Martin, O. J. F. (2018) · Biosensors · doi:10.3390/bios8020034 · Cited by 80
“932 mg/L, indicating that the commercial serum was withdrawn from humans with a clinically reported normal range [2].”
BackgroundDalgård, C., Nielsen, F., Morrow, J. D., Enghusen-Poulsen, H., Jonung, T., Hørder, M., & de Maat, M. P. M. (2008) · British Journal Of Nutrition · doi:10.1017/s0007114508995660 · Cited by 78
“In addition to being markers of vascular inflammation, it has recently also been suggested that CRP may causally contribute to atherosclerosis((2,3)) indicating that reduction in CRP concentration per se may be clinically beneficial.”
Aronson, D., Boulos, M., Suleiman, A., Bidoosi, S., Agmon, Y., Kapeliovich, M. R., Beyar, R., Markiewicz, W., Hammerman, H., & Suleiman, M. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.04.014 · Cited by 79
C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo.
Devaraj, S., Dasu, M., Singh, U., Rao, L., & Jialal, I. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.05.060 · Cited by 81
Future Treatments for Chronic Obstructive Pulmonary Disease and Its Comorbidities
Barnes, P. J. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200807-069th · Cited by 88
“A small molecule inhibitor of CRP, 1,6bis(phosphocholine)-hexane, counteracts the effects of CRP in animal models, and therefore may be cardioprotective (57).”
Rhodes, B., Merriman, M. E., Harrison, A. A., Nissen, M. J., Smith, M., Stamp, L. K., Steer, S. E., Merriman, T. R., & Vyse, T. J. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000341 · Cited by 80
“This finding has been demonstrated in a rat model of myocardial infarction, where injection of human CRP is associated with a poor outcome; a situation that can be reversed by synthetic CRP inhibitors [23].”
BackgroundSelf-citationRYU, J., Lee, C., Shin, J. H., Park, C.-S., Kim, J., PARK, S., & Han, K. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.04.027 · Cited by 79
“1,6-bis (phosphocholine)hexane, which preoccupies complement-binding site on the surface of CRP pentamer, and the injection of which abrogated effects of human CRP to increase infarct size of rats [30].”
BackgroundStumpf, C., Sheriff, A., Zimmermann, S., Schaefauer, L., Schlundt, C., Raaz, D., Garlichs, C. D., & Achenbach, S. S. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.69327 · Cited by 83
“In diverse animal models, several authors have shown that CRP markedly increases the extent of myocardial damage produced by ischemic injury [13, 14, 24].”
BackgroundResultInfluentialDo we need to consider inflammatory markers when we treat atherosclerotic disease?
Athyros, V. G., Kakafika, A. I., Karagiannis, A. I., & Mikhailidis, D. P. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.02.026 · Cited by 81
Clinical Application of C-Reactive Protein Across the Spectrum of Acute Coronary Syndromes
Scirica, B. M., Morrow, D. A., Cannon, C. P., de Lemos, J. A., Murphy, S. A., Sabatine, M. S., Wiviott, S. D., Rifai, N., McCabe, C. H., Braunwald, E., et al. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2007.087957 · Cited by 75
“Recent observations, however, highlight the potential for the development of treatments directed at inflammation as a mediator of reperfusion injury in patients with ischemic injury ( 25 ).”
BackgroundInfluentialHypertriglyceridemia: A Neglected Risk Factor for Ischemic Stroke?
Liang, H., Zhang, Q., Hu, Y., Liu, G., & Qi, R. (2022) · Journal of Stroke · doi:10.5853/jos.2021.02831 · Cited by 85
“In a rat model of middle cerebral artery occlusion, human CRP infusion could increase the infarct volume, indicating that human CRP contributes to ischemic tissue damage.(106) Overall, the proinflammatory state elicited by hypertriglyceridemia may contribute to the pathogenesis of atherosclerosis and even alter the pa…”
BackgroundC-reactive protein promotes diabetic kidney disease in a mouse model of type 1 diabetes
Liu, F., Chen, H., Huang, X., Chung, A. C. K., Zhou, L., Fu, P., Szalai, A. J., & Lan, H. Y. (2011) · Diabetologia · doi:10.1007/s00125-011-2237-y · Cited by 78
Singh, U. S., Devaraj, S., Dasu, M. R. K., Ciobanu, D. A., Reusch, J. E. B., & Jialal, I. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000241572.05292.fb · Cited by 74
Bisoendial, R. J., Kastelein, J. J. P., Peters, S. L. M., Levels, J. H. M., Birjmohun, R. S., Rotmans, J. I., Hartman, D., Meijers, J. C. M., Levi, M. M., & Stroes, E. S. G. (2007) · Journal of Lipid Research · doi:10.1194/jlr.p600014-jlr200 · Cited by 82
“More recently, a small molecule inhibitor of CRP was also shown to limit infarct size in rats undergoing experimental myocardial infarction with concomitant CRP infusion ( 44 ).”
BackgroundMatsuo, R., Ago, T., Hata, J., Wakisaka, Y., Kuroda, J., Kuwashiro, T., Kitazono, T., Kamouchi, M., & on behalf of the Fukuoka Stroke Registry Investigators (2016) · PLoS ONE · doi:10.1371/journal.pone.0156790 · Cited by 80
“Further, administration of a specific small-molecule inhibitor of CRP to rats undergoing acute myocardial infarction abrogated the increase in infarct size and cardiac dysfunction produced by injection of human CRP [19].”
BackgroundSun, Z., Wu, S., Ma, J., Shi, H., Wang, L., Sheng, A., Yin, T., Sun, L., & Li, G. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b10729 · Cited by 75
High‐sensitivity C‐reactive protein: A predicative marker in severe asthma
Qian, F.-H., Zhang, Q., Zhou, L., Liu, H., Huang, M., Zhang, X. R., & Kai-sheng, Y. (2008) · Respirology · doi:10.1111/j.1440-1843.2008.01314.x · Cited by 74
Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance
Biasucci, L. M., Biasillo, G., & Stefanelli, A. (2010) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2010.277 · Cited by 77
“Moreover, growing evidence suggest a fascinating role for these markers as therapeutic guides, and, intriguingly, as direct therapeutic targets, in particular C-reactive protein (CRP) (3) and lipoprotein-associated phospholipase A2 (lp-PLA2) (4).”
BackgroundRies, W., Torzewski, J., Heigl, F., Pfluecke, C., Kelle, S., Darius, H., Ince, H., Mitzner, S. R., Nordbeck, P., Butter, C., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.591714 · Cited by 76
“CRP has long been thought to be pathogenetically involved in human cardiovascular disease (11, 13).”
BackgroundMethodInfluentialFcγ Receptors and Ligands and Cardiovascular Disease
Tanigaki, K., Sundgren, N. C., Khera, A., Vongpatanasin, W., Mineo, C., & Shaul, P. W. (2015) · Circulation Research · doi:10.1161/circresaha.116.302795 · Cited by 79
“This was associated with a 50% fall in LDL cholesterol and a 37% decrease in CRP.131 The event rate in the placebo group and the clinical impact observed with treatment and the associated fall in CRP suggested that elevated levels of CRP increased vascular disease risk in these subjects, even when the LDL cholesterol…”
InfluentialHaas, M. S., Alicot, E. M., Schuerpf, F., Chiu, I. M., Li, J., Moore, F. D., & Carroll, M. C. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq141 · Cited by 77
C-Reactive Protein and Coronary Heart Disease: All Said—Is Not It?
Strang, F., & Schunkert, H. (2014) · Mediators of Inflammation · doi:10.1155/2014/757123 · Cited by 81
Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease
Boehme, M., Kaehne, F., Kuehne, A., Bernhardt, W. M., Schröder, M., Pommer, W., Fischer, C., Becker, H., Müller, C., & Schindler, R. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl747 · Cited by 81
“However, in general, binding characteristics of PTX3 are far less thoroughly investigated compared with CRP [23].”
BackgroundEffects of Human C-Reactive Protein on Pathogenesis of Features of the Metabolic Syndrome
Pravenec, M., Kajiya, T., Zídek, V., Landa, V., Mlejnek, P., Šimáková, M., Šilhavý, J., Malínská, H., Oliyarnyk, O., Kazdová, L., et al. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.164350 · Cited by 77
Lane, T., Wassef, N., Poole, S., Mistry, Y., Lachmann, H. J., Gillmore, J. D., Hawkins, P. N., & Pepys, M. B. (2014) · Circulation Research · doi:10.1161/circresaha.114.302770 · Cited by 71
“Most of the known causative factors for atherosclerosis stimulate increased CRP production, but comprehensive genetic epidemiology studies provide no support for a pathogenic role of CRP.”
BackgroundSelf-citationShen, J., & Ordovas, J. M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.117754 · Cited by 70
“Moreover, associations are more likely observed in cases of disease with fatal outcomes (11, 17, 19), which is in line with the involvement of hsCRP concentrations in theincreaseofinfarctsize( 22 ),suggestingthepossibilitythatthroughaneffectonacute-phaseresponse(23), CRP genotype may be more strongly associated with m…”
BackgroundThiele, J. R., Zeller, J., Kiefer, J., Braig, D., Kreuzaler, S., Lenz, Y., Potempa, L. A., Grahammer, F., Huber, T. B., Huber-Lang, M. S., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00675 · Cited by 76
C-Reactive Protein and Coronary Heart Disease: Predictive Test or Therapeutic Target?
Hingorani, A. D., Shah, T., Casas, J. P., Humphries, S. E., & Talmud, P. J. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.115923 · Cited by 70
Statin Therapy for the Prevention of Atrial Fibrillation Trial (SToP AF trial)
Negi, S., Shukrullah, I., Veledar, E., Bloom, H. L., Jones, D. P., & Dudley, S. C. (2010) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2010.01925.x · Cited by 72
Khalafi, M., Akbari, A., Symonds, M. E., Pourvaghar, M. J., Rosenkranz, S. K., & Tabari, E. (2023) · Cytokine · doi:10.1016/j.cyto.2023.156303 · Cited by 69
Cardiac troponin I levels in canine pyometra
Hagman, R., Lagerstedt, A., Fransson, B. A., Bergström, A., & Häggström, J. U. (2007) · Acta veterinaria Scandinavica · doi:10.1186/1751-0147-49-6 · Cited by 69
“Measurement of these parameters was thus not useful to predict or identify dogs with increased cTnI levels despite previous reports of an association of TNF-α with cardiac troponin and the predictive value of CRP for cardiovascular events [7,36].”
BackgroundTrapping of palindromic ligands within native transthyretin prevents amyloid formation
Kolstoe, S. E., Mangione, P. P., Bellotti, V., Taylor, G. W., Tennent, G. A., Deroo, S., Morrison, A. J., Cobb, A. J. A., Coyne, A., McCammon, M. G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008255107 · Cited by 65
“Discussion Based on our successful previous work with pentraxins (14, 15), we designed a palindromic bivalent ligand, 4ajm15, intended to cross-link TTR molecules and thereby, trigger their depletion from the circulation (18).”
BackgroundMethodSelf-citationPinyorospathum, C., Chaiyo, S., Sae‐ung, P., Hoven, V. P., Damsongsang, P., Siangproh, W., & Chailapakul, O. (2019) · Microchimica Acta · doi:10.1007/s00604-019-3559-6 · Cited by 68
“The American Heart Association and the United States Centers for Disease Control and Prevention (AHA/CDC) provide the following criteria for CVD risk based on the level of CRP in human blood serum: concentrations of CRP less than 1, 1–3, and above 3 mg·L−1 represent low-risk, moderate risk, and high risk states, Elect…”
InfluentialThe Pentraxins 1975–2018: Serendipity, Diagnostics and Drugs
Pepys, M. B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02382 · Cited by 67
“[From reference (32) with permission of Macmillan Publishers Ltd].”
BackgroundSelf-citationC-Reactive Protein Triggers Cell Death in Ischemic Cells
Sheriff, A., Kayser, S., Brunner, P., & Vogt, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.630430 · Cited by 77
“This cannot be achieved by targeting its synthesis or using approaches, which take several days to affect CRP levels (16, 21, 76).”
BackgroundAn Intrinsically Disordered Motif Mediates Diverse Actions of Monomeric C-reactive Protein
Li, H., Wang, J., Meng, F., Jia, Z.-K., Su, Y., Bai, Q., Lv, L., Ma, F., Potempa, L. A., Yan, Y., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.695023 · Cited by 67
“With the aid of crystal structure, a specific inhibitor blocking the binding of pentameric CRP to phosphorylcholine has been developed showing beneficial effects in a rat model undergoing acute myocardial infarction (49).”
BackgroundGersch, M., Kolb, R., Alte, F., Groll, M., & Sieber, S. A. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4082793 · Cited by 68
C-reactive protein induces M-CSF release and macrophage proliferation
Devaraj, S., Yun, J.-M., Duncan-Staley, C., & Jialal, I. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0808458 · Cited by 66
“The majority of researchers in the CRP area in fact questions the existence of mCRP, as its presence has not been documented in human plasma or atheroma [12, 33, 34].”
BackgroundScientific and Clinical Challenges in Sepsis
Ulloa, L., Brunner, M., Ramos, L., & Deitch, E. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788453248 · Cited by 67
Leukocyte diversity in resolving and nonresolving mechanisms of cardiac remodeling
Tourki, B., & Halade, G. V. (2017) · The FASEB Journal · doi:10.1096/fj.201700109r · Cited by 70
“CRP blockade has been indicated as a promising therapeutic strategy in the MI setting (99).”
BackgroundLinking inflammation and thrombosis: Role of C-reactive protein
Fay, W. P. (2010) · World Journal of Cardiology · doi:10.4330/wjc.v2.i11.365 · Cited by 64
Kim, G., Park, S., Jung, J., Heo, K., Yoon, J., Kim, H., Kim, I. J., Kim, J. R., Lee, J. I., & Ree, M. (2009) · Advanced Functional Materials · doi:10.1002/adfm.200801680 · Cited by 63
Charradi, K., Sebaï, H., Elkahoui, S., Hassine, F. B., Limam, F., & Aouani, E. (2011) · Cardiovascular Toxicology · doi:10.1007/s12012-010-9101-z · Cited by 67
Neal, C. P., Mann, C. D., Sutton, C. D., Garcea, G., Ong, S. L., Steward, W. P., Dennison, A. R., & Berry, D. P. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.08.019 · Cited by 63
Targeting Transfusion-Related Acute Lung Injury: The Journey From Basic Science to Novel Therapies
Semple, J. W., McVey, M. J., Kim, M. S., Rebetz, J., Kuebler, W. M., & Kapur, R. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000002989 · Cited by 69
Ridker, P. M. (2014) · Circulation Research · doi:10.1161/circresaha.114.303215 · Cited by 75
“This latter rationale is part of the reason why the Pepys laboratory itself has continued to develop direct inhibitors of CRP as a potential treatment for existing cardiovascular disease.(6)”
BackgroundSelective apheresis of C-reactive protein: A new therapeutic option in myocardial infarction?
Sheriff, A., Schindler, R., Vogt, B., Abdel‐Aty, H., Unger, J. K., Bock, C., Gebauer, F., Slagman, A. C., Jerichow, T., Mans, D., et al. (2014) · Journal of Clinical Apheresis · doi:10.1002/jca.21344 · Cited by 62
“[16] reported that they used a small molecule that binds and inhibits human CRP to reduce the size of myocardial infarctions in a rat animal model.”
BackgroundMethodRajeshwar, K., Kaul, S., Al‐Hazzani, A. A., Babu, M. S., Balakrishna, N., Sharma, V., Jyothy, A., & Munshi, A. (2011) · Inflammation · doi:10.1007/s10753-011-9401-x · Cited by 61
Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD?
Man, S. F. P., Xing, L., Connett, J. E., Anthonisen, N. R., Wise, R. A., Tashkin, D. P., Zhang, X., Vessey, R., Walker, T., Celli, B. R., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00153207 · Cited by 61
“Overexpression of CRP locally amplifies tissue damage and increases infarction size in myocardium and brain [21].”
BackgroundEisenhardt, S. U., Habersberger, J., & Peter, K. (2009) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2010.02.002 · Cited by 69
“blocking agent that stabilizes CRP in an inactive decameric conformation has been shown to abolish this effect (Pepys et al. 2006).”
BackgroundAssociation Between C-Reactive Protein Genotype, Circulating Levels, and Aortic Pulse Wave Velocity
Schumacher, W., Cockcroft, J. R., Timpson, N. J., McEniery, C. M., Gallacher, J., Rumley, A., Lowe, G. D. O., Smith, G. D., Wilkinson, I. B., & Ben‐Shlomo, Y. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.117622 · Cited by 69
“In particular, a causal relation would raise the question of whether high-risk persons should have interventions to lower their CRP levels(2) and whether CRP antagonists merit evaluation in acute ischemia.(6) Two studies(7,8) even report that statin therapy reduces circulating CRP levels and thereby causes a reduction…”
BackgroundC-Reactive Protein Causes Adult-Onset Obesity Through Chronic Inflammatory Mechanism
Li, Q., Wang, Q., Xu, W., Ma, Y., Wang, Q., Eatman, D., You, S., Zou, J., Champion, J. P., Zhao, L., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00018 · Cited by 69
Mendelian Randomization: Application to Cardiovascular Disease
Timpson, N. J., Wade, K. H., & Smith, G. D. (2011) · Current Hypertension Reports · doi:10.1007/s11906-011-0242-7 · Cited by 71
Zeller, J., Bogner, B., McFadyen, J. D., Kiefer, J., Braig, D., Pietersz, G. A., Krippner, G. Y., Nero, T. L., Morton, C. J., Shing, K. S. C. T., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108165 · Cited by 61
Jeanes, H. L., Tabor, C. M., Black, D., EDERVEEN, A. G. H., & Gray, G. A. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0071 · Cited by 60
“We have recently shown that CRP can enhance infarct damage following permanent ligation of the coronary artery in the rat (Pepys et al. 2006).”
BackgroundSelf-citationYang, X., Hu, W., Zhang, Q., Wang, Y., & Sun, L. (2010) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2010.00548.x · Cited by 60
Heme Interacts with C1q and Inhibits the Classical Complement Pathway
Roumenina, L. T., Radanova, M., Atanasov, B. P., Popov, K. T., Kaveri, S. V., Lacroix-Desmazes, S., Frémeaux-Bacchi, V., & Dimitrov, J. D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.206136 · Cited by 60
van Durme, Y. M. T. A., Verhamme, K. M. C., Aarnoudse, A. L. H. J., Pottelberge, G. R. V., Hofman, A., Witteman, J. C. M., Joos, G., Brusselle, G., & Stricker, B. H. C. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200810-1540oc · Cited by 65
Kavsak, P. A., MacRae, A. R., Newman, A. M., Lustig, V., Palomaki, G. E., Ko, D. T., Tu, J. V., & Jaffe, A. S. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2006.10.025 · Cited by 59
Rosenzweig, B. A., Ross, N. T., Tagore, D. M., Jayawickramarajah, J., Saraogi, I., & Hamilton, A. D. (2009) · Journal of the American Chemical Society · doi:10.1021/ja809219p · Cited by 64
Novel markers of peripheral arterial disease
Khawaja, F. J., & Kullo, I. J. (2009) · Vascular Medicine · doi:10.1177/1358863x09106869 · Cited by 72
Metadata
- Authors
- Pepys, M. B., Hirschfield, G. M., Tennent, G. A., Ruth Gallimore, J., Kahan, M. C., Bellotti, V., Hawkins, P. N., Myers, R. M., Smith, M. D., Polara, A., Cobb, A. J. A., Ley, S. V., Andrew Aquilina, J., Robinson, C. V., Sharif, I., Gray, G. A., Sabin, C. A., Jenvey, M. C., Kolstoe, S. E., Thompson, D., & Wood, S. P.
- Affiliations
- The Royal Free Hospital (GB)
- University of Pavia (IT)
- University of Cambridge (GB)
- University of Edinburgh (GB)
- University of Southampton (GB)
- University of Sussex (GB)
- Corresponding author
- Pepys, Mark B.
- ORCID
- Venue
- Nature
- Published
- 2006-04
- Volume
- 440
- Issue
- 7088
- Pages
- 1217-1221
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2080883999
- Cited by
- 672
- References
- 31
- Citations by year
- 2026: 6 · 2025: 17 · 2024: 19 · 2023: 30 · 2022: 27 · 2021: 28 · 2020: 32 · 2019: 21 · 2018: 23 · 2017: 20 · 2016: 23 · 2015: 16 · 2014: 35 · 2013: 30 · 2012: 40
- FWCI
- 26.49
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- CentAUR (University of Reading) (acceptedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Figshare (submittedVersion)
- Funders
- Wellcome Trust
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- C-reactive protein, acute myocardial infarction, complement activation, cardioprotection, infarct size, neuroprotection, cerebral ischemia, small-molecule drug design, acute phase proteins, inflammation, stroke, drug repurposing
- MeSH terms
- Animals, C-Reactive Protein, Cardiovascular Diseases, Complement System Proteins, Hexanes, Humans, Male, Models, Molecular, Molecular Conformation, Myocardial Infarction, Phosphorylcholine, Drug Design, Rats, Wistar, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.